<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054859</url>
  </required_header>
  <id_info>
    <org_study_id>TA-015</org_study_id>
    <nct_id>NCT01054859</nct_id>
  </id_info>
  <brief_title>A Phase I Crossover Study of the Hemodynamic Interactions of Avanafil &amp; Alcohol in Healthy Male Subjects.</brief_title>
  <official_title>A PHASE I, A SINGLE-CENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, THREE-PERIOD, THREE-WAY CROSSOVER STUDY OF THE HEMODYNAMIC INTERACTIONS OF AVANAFIL AND ALCOHOL IN HEALTHY MALE SUBJECTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is primarily to evaluate whether taking avanafil with alcohol&#xD;
      causes the blood pressure to fall.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a single-centre double-blind, randomized, placebo-controlled, three-period,&#xD;
      three-way crossover study, in which each subject will be randomized to receive each of the&#xD;
      following three treatments with a washout period of at least 5 days between treatments:&#xD;
&#xD;
        -  Treatment A: a single oral dose of one 200 mg avanafil tablet plus an oral dose of&#xD;
           alcohol drink mixed with fruit juice (0.5 g of absolute ethanol per kilogram of body&#xD;
           weight).&#xD;
&#xD;
        -  Treatment B: a single oral dose of one placebo tablet plus an oral dose of alcohol drink&#xD;
           mixed with fruit juice (0.5 g of absolute ethanol per kilogram of body weight).&#xD;
&#xD;
        -  Treatment C: a single oral dose of one 200 mg avanafil tablet plus an oral dose of&#xD;
           placebo drink mixed with fruit juice.&#xD;
&#xD;
      For each treatment period, Dinamap (or DataScope) automatic measurements of supine blood&#xD;
      pressure and pulse rate will be taken pre-dose and every 15 minutes for 4 hours post-dose.&#xD;
      Alcohol levels using a breathalyzer will be measured at pre-dose and up to 8 hours post dose&#xD;
      during all 3 treatments by designated unblinded personnel. Subjects should be supine for at&#xD;
      least 5-10 minutes before the blood pressure and heart rate measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For supine systolic (SBP) and diastolic (DBP) blood pressure, the area under effect-time curve (AUEC0- t), expressed as change from baseline and the maximum decrease in blood pressure. For supine pulse rate, maximum increase in pulse rate.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 g/Kg alcohol plus 200 mg avanafil tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5 g/kg alcohol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg avanafil tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avanafil</intervention_name>
    <description>200 mg avanafil tablet QD plus 0.5 g/kg alcohol</description>
    <arm_group_label>Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>alcohol</intervention_name>
    <description>0.5 g/kg alcohol</description>
    <arm_group_label>Treatment B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>avanafil</intervention_name>
    <description>200 mg avanafil tablet QD</description>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male subjects,&#xD;
&#xD;
          -  either 21 to 45 years of age,&#xD;
&#xD;
          -  must be medically healthy with no clinically significant screening results.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major exclusion criteria include: history or clinical evidence of clinically relevant&#xD;
             cardiovascular (including thromboembolic disorders), hepatic, renal, hematological,&#xD;
             endocrine, pulmonary, gastrointestinal, psychiatric or neurological impairment; any&#xD;
             clinically significant laboratory abnormalities as judged by the investigator;&#xD;
             systolic blood pressure &lt; 90 or &gt;150 mmHg; diastolic blood pressure &lt; 50 or &gt; 95 mmHg;&#xD;
&#xD;
          -  allergy to or previous adverse events with PDE5 inhibitors, alcohol or their&#xD;
             constituents; use of prescription or over-the-counter drugs that are known to&#xD;
             interfere with metabolism by the cytochrome P450 3A4 enzyme within 30 days of Day 1&#xD;
             dosing (Period 1);&#xD;
&#xD;
          -  use of any investigational drug within 30 days of Day 1 dosing (Period 1);&#xD;
&#xD;
          -  use of any prescription or over-the-counter drugs or herbal remedies within 14 days of&#xD;
             Day 1 dosing (Period 1);&#xD;
&#xD;
          -  history of alcohol or drug abuse within 18 months, history of smoking within 6 months;&#xD;
             positive breath alcohol, positive cotinine test or positive urine drug screen at&#xD;
             screening or on Day -1;&#xD;
&#xD;
          -  positive serology for HIV, HCV, HBsAg. Additional exclusion criteria are listed in&#xD;
             Section 4.2.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyin Yee, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Wesley Day, VP Clinical Development</name_title>
    <organization>Vivus, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

